US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Should you claim child benefit? What it's worth
Child benefit was once a simple univeral payment that went to all those with children but a shake-up2024-05-21- Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
China Focus: China Rolls out Private Pension Scheme for Aging Population
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Meet China's first corgi police dog
BEIJING, March 28 (Xinhua) -- Breaking stereotypes, Fu Zai, a six-month-old corgi, is ready to sniff2024-05-21Germany's foreign minister visits Kyiv as Ukraine battles to hold off a Russian offensive
KYIV, Ukraine (AP) — Germany’s foreign minister arrived in Kyiv on Tuesday in the latest public disp2024-05-21China Moves Forward in Balanced Education Efforts
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21
atest comment